Stockreport

Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study

Akari Therapeutics Plc - American Depositary Shares  (AKTX) 
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
PDF Phase III interim data on the first eight PNH patients who were all transfusion dependent at entry to the CAPSTONE trial show that all four patients randomized to nomaco [Read more]